IGF-1 Explored for Anti-Aging Gene Effects on UVB-Damaged Geriatric Skin
Background
Aging skin undergoes significant molecular changes, making it more susceptible to environmental damage like UVB radiation. This vulnerability can lead to impaired healing and increased risk of skin conditions. While the effects of UVB on young skin are well-documented, less is known about how geriatric skin responds at a genetic level, particularly regarding potential protective interventions. This study aims to identify specific gene expression changes in geriatric skin following UVB exposure and assess the modulatory effects of Insulin-like Growth Factor 1 (IGF-1).
Results
As an ongoing clinical trial (recruiting since September 2019), specific gene expression results are not yet available. However, the study aims to identify and quantify the molecular signatures of UVB-induced damage in both young and geriatric skin, and crucially, to determine how IGF-1 intervention alters these signatures in older individuals. Researchers hypothesize that IGF-1 will modulate pathways related to inflammation, cellular repair, and extracellular matrix integrity, potentially restoring a more youthful gene expression profile. The study will compare gene expression profiles between UVB-treated and IGF-1/UVB-treated skin areas in geriatric adults, as well as against UVB-treated young adult skin. > The primary objective is to determine if local Insulin-Like Growth Factor 1 administration can mitigate detrimental UVB-induced gene expression changes associated with aging in geriatric skin.
Why It Matters
This research is critical for understanding the molecular mechanisms behind skin aging and its response to environmental stressors like UVB. If Insulin-Like Growth Factor 1 proves effective in modulating gene expression to counteract UVB damage in geriatric skin, it could pave the way for novel preventative and therapeutic strategies for age-related skin conditions. The findings could inform the development of topical or injectable IGF-1 formulations to protect vulnerable older skin from sun damage and accelerate healing. Future steps would involve larger Phase II trials to assess clinical efficacy and safety in a broader population.